F.D.A. Declines to Approve MDMA Therapy, Seeking More Study
The New York Times
The agency said there was insufficient data to allow the use of a treatment for PTSD that involves the drug known as Ecstasy.
The Food and Drug Administration on Friday declined to approve MDMA-assisted therapy for the treatment of post-traumatic stress disorder, dealing a serious blow to the nascent field of psychedelic medicine and dashing the hopes of many Americans who are desperate for new treatments.
The F.D.A. said there was insufficient data to allow its use, and it asked the company seeking approval for the treatment, Lykos Therapeutics, to conduct an additional clinical trial to assess whether the drug, commonly known as Ecstasy or molly, would be safe and effective.
An additional clinical trial could add years, and millions of dollars, to the approval process.
If approved, MDMA would have become the first psychedelic compound to be regulated by federal health authorities. Supporters of psychedelic medicine were deeply disappointed, and some said they were stunned, having assumed the therapy’s promising data would overcome flaws in the company’s clinical trials, which had been designed in consultation with F.D.A. scientists.
“This is an earthquake for those in the field who thought F.D.A. approval would be a cinch,” said Michael Pollan, the best-selling author and co-founder of the UC Berkeley Center for the Science of Psychedelics. His book, “How to Change Your Mind,” helped catalyze public interest in the therapeutic potential of psychoactive compounds, demonized during the nation’s long war on drugs.
But the agency’s decision had not been entirely unexpected, after a group of independent experts convened by the F.D.A. to evaluate Lykos’s data met in June and did not recommend the treatment. On two central questions, the experts voted overwhelmingly that the company had not proven the treatment was effective, and that the drug therapy’s benefits did not outweigh the risks.
A new study found that women who went through so-called premature menopause had 40 percent more fatal and nonfatal heart attacks over the course of their lives.
In a stroke of luck, astronomers saw the comet C/2025 K1 (ATLAS) break into four or five fragments in November after it passed close to the sun.
New A.I. bots can do more than just chat. They can edit files, send emails, book trips and cause trouble.
The series, “inspired” by the story of a royal dresser later convicted of murder, is getting added attention over the former Duchess of York’s ties to Jeffrey Epstein.
Lawyers for both sides in the federal lawsuit, brought by six medical organizations, are trying to understand the ramifications of the judge’s decision.
Andy Weir discusses his science-fueled novel “Project Hail Mary,” which has been adapted into a film that opens in theaters on Friday.
After years of criticism and financial risk, Palantir, Anthropic and small start-ups are generating rewards from their investments in defense tech.
In a legal filing, the government said it questioned whether the A.I. start-up could be a “trusted partner” in wartime, which led it to label the company a supply chain risk.
Before humanity sent satellites, telescopes, humans and weapons into space, Robert Goddard experimented with the first liquid-fueled rocket on his aunt’s farm.
A draft State Department memo outlines ways the Trump administration may ratchet up pressure on the African country by ending health support “on a massive scale.”
A Florida bill that would have regulated artificial intelligence, backed by Gov. Ron DeSantis, failed to gain traction after President Trump made it clear he did not want states to rein in the technology.
The series, “inspired” by the story of a royal dresser later convicted of murder, is getting added attention over the former Duchess of York’s ties to Jeffrey Epstein.
After postponing launch opportunities in February and March, the agency determined that four astronauts could proceed toward the first crewed lunar journey in more than 50 years.